Conclusions: Our results identify that activation of the PRMT1/HNF-4α/PGC-1α signaling is a potential therapeutic strategy for combating non-alcoholic fatty liver disease of obese subjects. This evidence concerns the gene HNF4A and metabolic dysfunction-associated steatotic liver disease.